232 related articles for article (PubMed ID: 9367459)
1. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis.
Bates RD; Nahata MC; Jones JW; McCoy K; Young G; Cox S; Barson WJ
Chest; 1997 Nov; 112(5):1208-13. PubMed ID: 9367459
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis.
Bragonier R; Brown NM
J Antimicrob Chemother; 1998 Jul; 42(1):103-6. PubMed ID: 9700537
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.
Master V; Roberts GW; Coulthard KP; Baghurst PA; Martin A; Roberts ME; Onishko CR; Martin AJ; Linke RJ; Holmes M; Jarvinen A; Kennedy D; Colebatch KA; Hansman D; Parsons DW
Pediatr Pulmonol; 2001 May; 31(5):367-76. PubMed ID: 11340683
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
Lam W; Tjon J; Seto W; Dekker A; Wong C; Atenafu E; Bitnun A; Waters V; Yau Y; Solomon M; Ratjen F
J Antimicrob Chemother; 2007 Jun; 59(6):1135-40. PubMed ID: 17446242
[TBL] [Abstract][Full Text] [Related]
5. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.
Prescott WA; Nagel JL
Pharmacotherapy; 2010 Jan; 30(1):95-108. PubMed ID: 20030477
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
Massie J; Cranswick N
J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
Vic P; Ategbo S; Turck D; Husson MO; Launay V; Loeuille GA; Sardet A; Deschildre A; Druon D; Arrouet-Lagande C
Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis.
Brigg Turner R; Elbarbry F; Biondo L
J Chemother; 2016 Aug; 28(4):304-7. PubMed ID: 26430825
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis.
Hennig S; Standing JF; Staatz CE; Thomson AH
Clin Pharmacokinet; 2013 Apr; 52(4):289-301. PubMed ID: 23420517
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO
Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
van Koningsbruggen-Rietschel S; Heuer HE; Merkel N; Posselt HG; Staab D; Sieder C; Ziegler J; Krippner F; Rietschel E
J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719
[TBL] [Abstract][Full Text] [Related]
12. Suggestions for the optimization of the initial tobramycin dose in adolescent and adult patients with cystic fibrosis.
Touw DJ; Vinks AA; Heijerman HG; Hermans J; Bakker W
Ther Drug Monit; 1994 Apr; 16(2):125-31. PubMed ID: 8009558
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.
Geller DE; Pitlick WH; Nardella PA; Tracewell WG; Ramsey BW
Chest; 2002 Jul; 122(1):219-26. PubMed ID: 12114362
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis.
Touw DJ; Knox AJ; Smyth A
J Cyst Fibros; 2007 Sep; 6(5):327-33. PubMed ID: 17276147
[TBL] [Abstract][Full Text] [Related]
16. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
Hennig S; Norris R; Kirkpatrick CM
Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
[TBL] [Abstract][Full Text] [Related]
17. An in vivo assessment of the tobramycin/ticarcillin interaction in cystic fibrosis patients.
Roberts GW; Nation RL; Jarvinen AO; Martin AJ
Br J Clin Pharmacol; 1993 Oct; 36(4):372-5. PubMed ID: 12959319
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
[TBL] [Abstract][Full Text] [Related]
19. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis.
Aminimanizani A; Beringer PM; Kang J; Tsang L; Jelliffe RW; Shapiro BJ
J Antimicrob Chemother; 2002 Oct; 50(4):553-9. PubMed ID: 12356801
[TBL] [Abstract][Full Text] [Related]
20. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
